Cantor Fitzgerald Reiterates Overweight on Mereo BioPharma Group, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Mereo BioPharma Group (NASDAQ:MREO) and maintained a $7 price target.
July 22, 2024 | 3:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Mereo BioPharma Group (NASDAQ:MREO) and maintained a $7 price target.
The reiteration of an Overweight rating and the maintenance of a $7 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100